Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multiple Dose Opioid Challenge Study to Assess Blockade of Subjective Opioid Effects of CAM2038 q1w (Buprenorphine FluidCrystal® Subcutaneous Injection Depots) In Adults With Opioid Use Disorder

NCT02611752 is registered in ClinicalTrials.gov with Braeburn Pharmaceuticals as lead sponsor.

NCT NCT02611752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02611752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multiple Dose Opioid Challenge Study to Assess Blockade of Subjective Opioid Effects of CAM2038 q1w (Buprenorphine FluidCrystal® Subcutaneous Injection Depots) In Adults With Opioid Use Disorder
Lead sponsor
Braeburn Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2015
Completion date
April 30, 2016
Enrollment
47 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

moderate or severe opioid use disorder